Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Deepak Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI
Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI Advisory Board
J. William McEvoy MB BCh BAO, MEd, MHS, PhD, FRCPI
J. William McEvoy MB BCh BAO, MEd, MHS, PhD, FRCPI Advisory Board
Paul Thompson MD
Paul D. Thompson MD Advisory Board
See All Experts
featured
Published in Cardiology

Journal Scan / Research · March 10, 2022

Canagliflozin Improves Health Status in Patients With Heart Failure

Nature Medicine

 

 Save  Recommend
 Share

Additional Info

Nature Medicine
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
Nat. Med. 2022 Feb 28;[EPub Ahead of Print], JA Spertus, MC Birmingham, M Nassif, CV Damaraju, A Abbate, J Butler, DE Lanfear, I Lingvay, MN Kosiborod, JL Januzzi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated